MA34724B1 - Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase - Google Patents
Nouvelle forme d'administration d'un inhibiteur de l'enképhalinaseInfo
- Publication number
- MA34724B1 MA34724B1 MA35980A MA35980A MA34724B1 MA 34724 B1 MA34724 B1 MA 34724B1 MA 35980 A MA35980 A MA 35980A MA 35980 A MA35980 A MA 35980A MA 34724 B1 MA34724 B1 MA 34724B1
- Authority
- MA
- Morocco
- Prior art keywords
- enkephalinase
- inhibitor
- administration
- novel form
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne une nouvelle formulation d'un inhibiteur de l'enképhalinase, tel que le racécadotril ou le dexécadotril, le procédé de préparation associé, et son utilisation dans le traitement de la diarrhée.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10306397A EP2462922A1 (fr) | 2010-12-10 | 2010-12-10 | Nouvelle forme d'administration pour inhibiteurs de l'enképhalinase |
PCT/EP2011/072315 WO2012076691A1 (fr) | 2010-12-10 | 2011-12-09 | Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34724B1 true MA34724B1 (fr) | 2013-12-03 |
Family
ID=45092498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35980A MA34724B1 (fr) | 2010-12-10 | 2013-06-06 | Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase |
Country Status (31)
Country | Link |
---|---|
US (1) | US9439853B2 (fr) |
EP (2) | EP2462922A1 (fr) |
JP (1) | JP5847192B2 (fr) |
KR (1) | KR101837685B1 (fr) |
CN (1) | CN103338749B (fr) |
AP (1) | AP3787A (fr) |
AU (1) | AU2011340500B2 (fr) |
BR (1) | BR112013014388A2 (fr) |
CA (1) | CA2820835C (fr) |
CO (1) | CO6731092A2 (fr) |
CY (1) | CY1123056T1 (fr) |
DK (1) | DK2648696T3 (fr) |
EA (1) | EA022730B1 (fr) |
EC (1) | ECSP13012665A (fr) |
ES (1) | ES2791710T3 (fr) |
HR (1) | HRP20200555T1 (fr) |
HU (1) | HUE049273T2 (fr) |
IL (1) | IL226775A (fr) |
LT (1) | LT2648696T (fr) |
MA (1) | MA34724B1 (fr) |
ME (1) | ME03769B (fr) |
MX (1) | MX354858B (fr) |
NZ (1) | NZ611597A (fr) |
PL (1) | PL2648696T3 (fr) |
PT (1) | PT2648696T (fr) |
RS (1) | RS60197B1 (fr) |
SG (1) | SG191068A1 (fr) |
SI (1) | SI2648696T1 (fr) |
TN (1) | TN2013000239A1 (fr) |
UA (1) | UA111835C2 (fr) |
WO (1) | WO2012076691A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2987268B1 (fr) | 2012-02-28 | 2014-07-11 | Ammtek | Formulations liquides de sulfamides hypoglycemiants |
US9801819B2 (en) | 2012-06-28 | 2017-10-31 | Johnson & Johnson Consumer Inc. | Racecadotril compositions |
US9114171B2 (en) * | 2012-06-28 | 2015-08-25 | Mcneil-Ppc, Inc. | Racecadotril liquid compositions |
PT2866802T (pt) * | 2012-06-28 | 2016-09-05 | Johnson & Johnson Consumer Inc | Composições líquidas racecadotril |
RU2632441C2 (ru) * | 2012-06-28 | 2017-10-04 | МакНЕЙЛ-ППС, ИНК. | Липидные композиции рацекадотрила |
CN105848643A (zh) * | 2013-12-23 | 2016-08-10 | 强生消费者公司 | 消旋卡多曲组合物 |
ES2549127T1 (es) | 2014-03-10 | 2015-10-23 | Galenicum Health S.L. | Composiciones farmacéuticas que comprenden un principio activo |
ES2555484T1 (es) | 2014-05-26 | 2016-01-04 | Galenicum Health S.L. | Composiciones farmacéuticas que contienen un agente activo |
MA40859A (fr) | 2014-10-29 | 2017-09-05 | Johnson & Johnson Consumer Inc | Particules de cadotril |
CN105125477A (zh) * | 2015-08-19 | 2015-12-09 | 黑龙江佰彤儿童药物研究有限公司 | 一种含消旋卡多曲的药物制剂及制备方法 |
IT201700099690A1 (it) * | 2017-09-06 | 2019-03-06 | Abiogen Pharma Spa | Composizione per l’integrazione di calcio |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
DK1294372T3 (da) | 2000-06-23 | 2005-09-19 | Bioprojet Soc Civ | Törpulverformulering der omdanner racecadotril |
GB0015490D0 (en) * | 2000-06-23 | 2000-08-16 | Smithkline Beecham Lab | Novel formulations |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
EP1563848A1 (fr) * | 2004-02-12 | 2005-08-17 | Bioprojet | Nouvelles combinaisons d' agents antiémétiques avec inhibiteurs de l'enképhalinase |
WO2007102171A2 (fr) * | 2006-03-07 | 2007-09-13 | Panacea Biotec Ltd | Nouveaux sels de l'acide 1h-1-benzazépine-1-acétique, préparation de ceux-ci et composition pharmaceutique comprenant ceux-ci |
CN101103960B (zh) * | 2006-07-14 | 2010-12-08 | 海南盛科生命科学研究院 | 一种含有消旋卡多曲的干混悬剂及其制备方法 |
TW201014830A (en) | 2008-09-30 | 2010-04-16 | Theravance Inc | Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid |
-
2010
- 2010-12-10 EP EP10306397A patent/EP2462922A1/fr not_active Withdrawn
-
2011
- 2011-09-12 UA UAA201308676A patent/UA111835C2/uk unknown
- 2011-12-09 CA CA2820835A patent/CA2820835C/fr active Active
- 2011-12-09 SG SG2013044250A patent/SG191068A1/en unknown
- 2011-12-09 AU AU2011340500A patent/AU2011340500B2/en active Active
- 2011-12-09 LT LTEP11797216.6T patent/LT2648696T/lt unknown
- 2011-12-09 PT PT117972166T patent/PT2648696T/pt unknown
- 2011-12-09 KR KR1020137015290A patent/KR101837685B1/ko active IP Right Grant
- 2011-12-09 US US13/992,577 patent/US9439853B2/en active Active
- 2011-12-09 ME MEP-2020-71A patent/ME03769B/fr unknown
- 2011-12-09 EA EA201300688A patent/EA022730B1/ru unknown
- 2011-12-09 RS RS20200446A patent/RS60197B1/sr unknown
- 2011-12-09 CN CN201180064672.3A patent/CN103338749B/zh active Active
- 2011-12-09 WO PCT/EP2011/072315 patent/WO2012076691A1/fr active Application Filing
- 2011-12-09 BR BR112013014388A patent/BR112013014388A2/pt not_active Application Discontinuation
- 2011-12-09 SI SI201131867T patent/SI2648696T1/sl unknown
- 2011-12-09 ES ES11797216T patent/ES2791710T3/es active Active
- 2011-12-09 PL PL11797216T patent/PL2648696T3/pl unknown
- 2011-12-09 HU HUE11797216A patent/HUE049273T2/hu unknown
- 2011-12-09 JP JP2013542560A patent/JP5847192B2/ja active Active
- 2011-12-09 DK DK11797216.6T patent/DK2648696T3/da active
- 2011-12-09 NZ NZ611597A patent/NZ611597A/en unknown
- 2011-12-09 MX MX2013006492A patent/MX354858B/es active IP Right Grant
- 2011-12-09 EP EP11797216.6A patent/EP2648696B1/fr active Active
- 2011-12-09 AP AP2013006971A patent/AP3787A/en active
-
2013
- 2013-06-03 TN TNP2013000239A patent/TN2013000239A1/fr unknown
- 2013-06-06 EC ECSP13012665 patent/ECSP13012665A/es unknown
- 2013-06-06 MA MA35980A patent/MA34724B1/fr unknown
- 2013-06-06 IL IL226775A patent/IL226775A/en active IP Right Grant
- 2013-06-11 CO CO13139839A patent/CO6731092A2/es unknown
-
2020
- 2020-04-06 HR HRP20200555TT patent/HRP20200555T1/hr unknown
- 2020-04-24 CY CY20201100374T patent/CY1123056T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34724B1 (fr) | Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase | |
MA32471B1 (fr) | Composés de borates esters et compositions pharmaceutiques contenant des composés | |
MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA33000B1 (fr) | Dicyanopyridine a substitution alkylamino et ses promedicaments d'ester d'acide amine | |
MA34019B1 (fr) | Aryltriazolone liée à un bis-aryle et son utilisation | |
MA35459B1 (fr) | Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit | |
MA34753B1 (fr) | Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes | |
MA38810A1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
MA37886A1 (fr) | Nouvelles pyridinones bicycliques | |
EA201400537A1 (ru) | 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА | |
FR3028753B1 (fr) | Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application | |
MA35638B1 (fr) | 2-thiopyrimidinones | |
BR112013028420A2 (pt) | tratamento de mieloma múltiplo | |
MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
MA20150279A1 (fr) | (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel | |
MA47736B1 (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
MA35937B1 (fr) | Composés substitués de chromane en tant que modulateurs des récepteurs de détection du calcium | |
MX335945B (es) | Composicion antifungica novedosa. | |
MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
MA39496A (fr) | Inhibiteurs de mtor spécifiques dans le traitement de l'adrénoleucodystrophie liée à l'x | |
TN2012000301A1 (fr) | Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée | |
MA38699A1 (fr) | Formulation orale pour le traitement de maladies cardiovasculaires | |
MA41809A (fr) | Biotine pour le traitement de la sclérose latérale amyotrophique |